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ABSTRACT 
Three adenosine analog antitumor agents, tubercidin, formycin, and 
8-azaadenosine were investigated for their affects on the synthesis and 
methylation of nuclear RNA (nRNA) in L1210 mouse leukemia cells in Vitro. 
Tubercidin inhibited both total RNA and DNA synthesis to the greatest 
extent (IC^q = 7 X 10"^M) as determined by filtration assay. These 
effects were not potentiated by the adenosine deaminase inhibitor 
2'-deoxycoformycin (dCF). Formycin and 8-azaadenosine demonstrated 
negligible inhibition in the absence of dCF; however, 1 X 10-^M formycin + 
dCF and 1 X 10~^M 8-azaadenosine 4- dCF each inhibited RNA synthesis by 
40%, both agents showing preferential inhibition of RNA vs DNA synthesis. 
DEAE Sephadex-Urea chromatography of alkaline hydrolysates of nRNA 
double-labeled with L-[methyl-^H] methionine and [ C] uridine demonstrated 
preferential inhibition of base methylation relative to nRNA synthesis 
for all three drugs. This effect was not observed for 2'-0-ribose 
methylation. Using denaturing polyacrylamide gel electrophoresis, ^ 
tubercidin was shown to preferentially inhibit methylation relative to [ C] 
uridine incorporation in both >18S nRNA and 4S nRNA; however, formycin 
and 8-azaadenosine demonstrated selective preferential inhibition of 
methylation relative to nRNA synthesis for 4S nRNA and > 18S nRNA 
respectively. Both tubercidin and formycin preferentially inhibited 
the synthesis of 4S nRNA while 8-azaadenosine showed no consistent 
dose response for selective inhibition of the synthesis of either 4S 
nRNA or >18S nRNA. Two dimensional thin-layer chromatography of 
enzymatically digested 4S nRNA revealed that the observed inhibition 
of base methylation was associated with reduced methylation of seven 
of the eight methylated nucleosides commonly found in 4S nRNA, with 
each drug apparently inhibiting a unique spectrum of RNA methyltransferases. 
These differential effects of tubercidin, formycin, and 8-azaadenosine 
on nRNA synthesis and methylation showed no consistent relationship with 
their glycosyl bond lengths or torsion angles. The results of this 
investigation indicate that tubercidin, formycin, and 8-azaadenosine 
can inhibit nRNA methylation, and the hypothesis in proposed that this 
effect may be related to their antitumor properties via the production 
of defectively methylated RNA which subsequently undergoes maturation 
arrest and degradation. 
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INTRODUCTION: 
In this study the effects of tubercidin, 8-azaadenosine, and 
formycin on nuclear RNA synthesis and methylation in L1210 mouse 
leukemia cells is investigated (Stern, 1980). These compounds, 
structurally related to adenosine, differ only in the imidazole 
portion of the purine ring of the parent compound (Fig. I). Recent 
advances in molecular genetics have implicated that methylation of 
RNA is important in the processing of this informational macromolecule. 
That RNA methylation and neoplasia may be related comes from studies 
showing that certain neoplastic tissues have increased tRNA methylase 
capacity (Borek, 1972). By investigating the effects of these 
structurally similar adenosine analogs on this important biological 
process, it is hoped that structure activity correlates can be deduced 
that maybe useful in the rational design of future antineoplastic agents. 
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-PART ONE- 
CELLULAR METABOLISM AND ANTITUMOR PROPERTIES OF TUBERCIDIN, 
FORMYCIN, AND 8-AZAADENOSINE 
1 

TUBERCIDIN 
Tubercidin, 4-amino-7-(B-D-ribofuranosyl) pyrrolo [2,3-d] pyrimidine, 
also known as 7 deazaadenosine is a pyrrolopyrimidine nucleoside 
antibiotic isolated from the broth of Streptomyces tubercidicus (Fig. I) 
(Anzae, 1957). The glycosyl bond length of tubercidin is 1.44 A, shorter 
than the glycosyl bond of adenosine which is 1.47A (Abola, 1973). Abola 
also found that the glycosyl torsion angle X: 0-C(1’)-N(9)-C(8) 
which describes the relative orientation of the sugar to the base of a 
crystal of tubercidin to be 73.0. Normally purines exist in the anti 
(X= 30 + 45°) conformation and it is this conformation that is required 
for normal duplex formation. Although in the solid state tubercidin 
occurs in the anti conformation, in aqueous solution both syn 
(X= 210 + 45°) and anti conformations were obtained by tubercidin and 
its 5' phosphate (Evans, 1975). Tubercidin is classified along with 
formycin and 8-azaadenosine as having a glycosyl torsion angle in the 
high anti range, intermediate between the classical anti and syn regions 
(Singh, 1977). As will be discussed below, the steric conformation of 
these analogs is important in determining their biochemical properties. 
The in Vitro cytotoxicity of tubercidin was quickly established for 
NF mouse sarcoma, human epidermoid carcinoma (KB), Ehrlich ascites cells, 
and Earles L cells (Duvall, 1962). Unlike studies using Streptococcus 
faecalis, cytotoxicity in the KB system was not reversible with purine 
or pyrimidine nucleosides of nucleotides (Smith, 1967; Bloch, 1967). In 
Vivo cytotoxicity studies were also performed where toxicity to the lung, 
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pancreas, kidneys, liver, and gonads was observed following intravenous 
administration of tubercidin (Owen, 1964). It was found that of 25 tumors 
tested tubercidin was confirmed to be active at non toxic doses against 
mice with ascitic sarcoma 180, Ehrlich asciti.es tumor, and Jensen sarcoma. 
Leukemia L1210 was not affected by tubercidin treatment. 
Because of these encouraging results phase I trials were undertaken. 
In 1970 Bisel et al selected 93 patients with a neoplastic spectrum 
including lung, kidney, sarcoma, colon, rectum, breast, head and neck, 
pancreas, melanoma, ovary, cervix, and stomach and administered intravenous 
tubercidin in a dose of 0.025 mg/kg/day, increasing this to 0.3 mg/kg/day 
in the absence of toxicity (Bisel, 1970). Such a course of treatment 
lasted for 10 consecutive days. Nephrotoxicity, manifested by proteinuria 
and azotemia, was observed in 18 cases with thrombophlebitis in 12. 
3 
Leukopenia to 2900-4500 leukocytes/mm occurred in 6 patients. Only 
three patients showed a response, 1 subjective and 2 both subjective and 
objective as assessed by a decrease in size of an intra-abdominal mass. 
All three had primarly pancreatic carcinoma of the islet cell type. 
There were six such patients studied. 
In an effort to avoid the problem of thrombophlebitis caused by 
IV administered tubercidin, it was observed that 80%-98% of tubercidin 
is absorbed by red blood cells (Smith, 1970). Most of the absorbed 
tubercidin exists intracellularly in the triphosphate form. There was 
no decrease in tubercidin loaded RBC survival as assessed by ~*"*~Cr tag 
experiments. When administered by rapid TV injection to dogs, 25% of 
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the drug appeared in the urine in 24 hours, but when red blood cells 
were used as a vehicle only 18% appeared in the urine in 21 days. These 
results were exploited by Grage who removed 300-500 ml of blood/patient, 
saturated it with tubercidin, and retransfused it at weekly intervals 
for 2 doses ranging from 200ug/kg to 1500 ug/kg in the 45 patients 
studied in his phase I trial (Grage, 1970). No thrombophlebitis was ob¬ 
served. Six cases of hematologic toxicity, 5 renal, 2 hepatic, and 1 
case of severe gastrointestinal toxicity were noted and there was no 
correlation with increased dose and the number of patients experiencing 
toxicity. Of the patients studied 4 had an objective regression, 3 
islet cell cancers and 1 metastatic stomach carcinoid to the cervical 
lymph nodes. It is of interest that in animal studies disappearance of 
the islets of Langerhans is consistently found in tubercidin treated 
animals, and it is this selective toxicity that may make tubercidin 
valuable in current chemotherapeutic protocols. The Central Oncology 
Group Protocol 7230A combines tubercidin, streptozotocin, and 5-flourouracil 
whereby tubercidin is mixed with 500 ml of the patient’s blood and 
retransfused over a four hour period in a dose of 1.5 mg/kg of body weight. 
5-Flourouracil at 12.5 mg/kg is given the same day and for an additional 
two days. After a 7-day rest period streptozotocin is added in a dose 
of 12.5 mg/kg in weekly doses alternating with 12.5 mg/kg of 5-flourouracil 
for the next six weeks. After a four week rest period the regimen is 
repeated if the hematologic picture is satisfactory. This protocol was 
valuable in treating 5 patients with extensive gastrinoma, all patients 
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feeling better and gaining from 3-35 pounds (Zollinger, 1976). Two of 
four patients with advanced islet cell carcinoma showed a dramatic 
initial response with the other two demonstrating prolonged survival on 
this protocol (Kraybill, 1976). In a four year study beginning in 1972, 
105 patients with adenocarcinoma or islet cell carcinoma of the pancreas 
were treated with the Central Oncology Group Protocol or 5-flourouracil 
alone (Awrich, 1979). The results indicated that for adenocarcinoma 
of the pancreas there was no significant difference in survival or time 
to progression of disease when these two treatments were compared. 
Eight patients with islet cell tumors were treated with the Central 
Oncology Group Protocol only with none experiencing progression of the 
disease and three demonstrating a partial response, where a partial 
response was defined as a 50% reduction in the product of the diameters 
of the lesions. 
Another example of the clinical efficacy of tubercidin is in the 
treatment of solitary nodular basal cell carcinoma (Burgess, 1974). 
Eight patients with this disorder were treated with a 0.5% ointment of 
tubercidin with all showing clinical disappearance of the tumor 
confirmed by biopsy and negative recurrence at 1 1/2 years post treatment. 
No signs of systemic toxicity were observed. Similar results were 
obtained by Klein, who in addition found higher doses of tubercidin 
ointment of value in the treatment of mycosis fungoides, reticulum 
cell sarcoma, squamous cell carcinoma, and soft tissue metastases of 
carcinoma of the breast (Klein, 1975) . 
The mechanism of the cytotoxicity of tubercidin has been investigated 
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on many different levels. Tubercidin has been shown to be cytotoxic to 
synchronized DON cells, isolated from a Chinese hamster fibroblast line, 
in all phases of the cell cycle at low dose, while at higher doses cells 
at the Gl-S boundry appeared more sensitive (Bhuyan, 1972). Studies 
on DNA, RNA, and protein synthesis using low dose tubercidin revealed 
marked inhibition in the synthesis of all these molecules, 84%, 86%, 
and 88% inhibition respectively. Simultaneous inhibition of DNA, RNA, 
and protein synthesis was also observed to occur in another mouse 
fibroblast line (Acs, 1964). This author also observed certain cytologic 
changes when the cells were exposed to tubercidin. These changes did 
not occur when the cells were pretreated with actinomycin. This is an 
interesting result in lieu of the data obtained by Bhuyan which suggests 
increased sensitivity of cells to tubercidin at a time in the cell cycle 
dominated by RNA transcription. 
Further insight into the biochemical basis of the cytotoxicity of 
tubercidin comes from work with sublines of human epidermoid carcinoma 
(H.Ep.#2) cells with deficiencies in adenosine kinase, a subline with 
a combined deficiency in adenosine kinase and hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT), and another line with a combined 
deficiency in adenosine kinase and adenine phosphoribosyl transferase 
(APRT). By determining the sensitivities of these sublines to an array 
of purine ribonucleoside analogs it was deduced that the three pathways 
illustrated in (Fig. II) could be utilized by these compounds in gaining 
entrance into the nucleotide pool (Bennett, 1966) . Tubercidin was 
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shown to utilize pathway I, involving adenosine kinase, as its major 
anabolic pathway although pathway II, involving nucleoside phosphorylase 
and APRT is also used, albeit to a much lesser degree. Confirming this 
were studies demonstrating that tubercidin is in fact a substrate not 
only for adenosine kinase from H.Ep.#2 cells, being phosphorylated 4X 
faster than adenosine, but for adenosine kinase isolated from yeast and 
sarcoma 180 cells as well (Schnebli, 1967; Bloch, 1967). Data showing 
that mouse fibroblasts are insensitive to the aglycone of tubercidin, 
and that adenosine phosphorylase and APRT isolated from extracts of 
jS. faecalis did not utilize tubercidin also suggests that pathway II is 
not a major anabolic pathway (Acs, 1964; Bloch, 1967). Interestingly, 
pathway III was shown to be the major metabolic pathway for adenosine in 
this cell system. It is no surprise that tubercidin is not metabolized 
via pathway III since this adenosine analog has been shown not to be a 
substrate for adenosine deaminase (ADA) purified from intestinal mucosa, 
human erythrocytes, or P388 murine leukemia cells (Bloch, 1967; Agarwal, 
1975; Adamson, 1977). Adamson demonstrated that tubercidin inhibited 
the growth of P388 murine leukemia cells to the same degree, with or 
without 2’deoxycoformycin (dCF), a competitive inhibitor of adenosine 
-12 
deaminase (Ki = 2.5 X 10 M for human erythrocyte ADA). Characterization 
of the acid soluble pool of mouse fibroblasts exposed to tubercidin 
revealed 5-10% Tu5'MP, 8-15% Tu5'DP, and 75-85% Tu5'TP, with no guanine 
analogs detected (Acs, 1964). It is perhaps the inability of tubercidin 
to be metabolized via pathway III that accounts for its lack of conversion 
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to guanine nucleotides. 
Numerous studies have demonstrated that tubercidin not only becomes 
a member of the nucleotide pool but perturbs that pool as well. Bloch 
demonstrated that tubercidin interfered with the formation of ATP from 
AMP in both the sarcoma 180 and J3. faecalis systems, a result confirmed 
in mouse leukemia EL4 cells where up to 80% of cellular ATP was lost 
with a concomitent build up of tubercidin triphosphate and its 3'5’ cyclic 
analog (Bloch, 1967; Zimmerman, 1978). Using azaserine treated H.Ep.#2 
cells, tubercidin was as effective as adenosine in producing a 50% 
reduction in formylglycinamide ribonucleotide and ribonucleoside levels 
(Bennett, 1964). This result was investigated further in Ehrlich ascites 
14 , 
tumor cells in Vitro, whereby using ribonucleotide synthesis from l CJ 
adenine as a measure of the rate of 5 phosphoribosyl-l-pyrophosphate 
(PRPP) synthesis, tubercidin was shown to inhibit PRPP synthesis (Henderson, 
1965) . Therefore, while tubercidin has been shown by several studies to 
inhibit de novo purine biosynthesis in a variety of systems, the site 
of this inhibition appears to be phosphoribose pyrophosphokinase and 
not amidophosphoribosyl transferase as one would have guessed. 
Evidence that tubercidin is capable of entering the deoxyribonucleotide 
pool comes from studies where tubercidin was used as a substrate and 
allosteric modulator for prokaryotic ribonucleotide reductase. E. Coli 
ribonucleotide reductase, which reduces ribonucleoside diphosphates 
using dGTP and TTP as positive allosteric modulators, acted on tubercidin 
diphosphate with 40% of the activity demonstrated for ADP, with dGTP 
but not TTP serving as a positive allosteric modulator (Chassy, 1968). 
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Unlike the EL Coli enzyme, ribonucleotide reductase from Lactobacillus 
leichmanii utilizes ribonucleoside triphosphates with dGTP and 2’dATP 
as "prime effectors" (Suhadolnik, 1968). Tubercidin triphosphate 
reduction was 75% of ATP with dGTP acting as a better positive modulator 
than 2’dATP for this reduction. In addition to this, tubercidin 
triphosphate was found to be 50% as effective as 2'dATP as a positive 
allosteric modulator for CTP reduction. While 2’dATP is a negative 
modulator for ATP reduction, tubercidin triphosphate had a negligible 
effect. The results of these studies indicate that at least in prokaryotes 
tubercidin is a substrate for reduction to its deoxy analog, supplying 
precursors for incorporation into DNA, and that tubercidin can interact, 
albeit in a modified way with the regulatory site of this enzyme. 
As has been reviewed above, tubercidin is able to enter the 
nucleotide pool and can be converted to deoxy as well as mono, di, and 
triphosphate forms. Evidence exists that these nucleotide precursors 
are capable of entering anabolic pathways used in the formation of 
nucleotide containing cofactors as in the case of nicotinamide-deaza- 
adenine dinucleotide isolated from tubercidin treated S_. faecalis 
(Bloch, 1967). Tubercidin incorporation into DNA and RNA has been 
established in bacteria, mouse fibroblasts, mouse L5178y cells, and the 
single stranded RNA Mengo virus (Bloch, 1967; Acs, 1964; Seibert, 1978). 
Seibert demonstrated that with L5178y cells treated with a dose of 
tubercidin of 0.05ug/ml 21% is incorporated into acid insoluble material 
with 15% of the tubercidin incorporated distributed into DNA and 84% 
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into total RNA. Acs, using tubercidin at a dose of 1 ug/ml to treat 
mouse fibroblast L cells, found a total incorporation of tubercidin 
into acid insoluble material of only 5% with a distribution of tubercidin 
into RNA 2.7X that of DNA (Acs, 1964). It appears then that incorporation 
of tubercidin into acid insoluble material varies with the cell system 
studied, and that tubercidin appears to accumulate in RNA to a greater 
extent than DNA. 
Several studies have demonstrated that tubercidin interferes with 
RNA transcription and processing. This evidence will be presented 
later. 
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FORMYCIN 
Formycin A or 7-amino-3-(B-D-ribofuranosyl)-pyrazolo [4,3-d] 
pyrimidine was originally isolated from culture filtrates of Nocardia 
Interforma (Hori, 1964). As can be seen from (Fig. I), the structure of 
formycin (formycin will be used to refer to formycin A) is similar to 
adenosine except that C8 and N9 have been interchanged causing an 
increase in the length of this CC glycosyl bond to 1.55 A (Ward and 
Reich, 1968). The glycosyl torsion angle is 109.5, much larger than 
the angle for tubercidin, but like tubercidin exists in a high anti 
configuration (Prusiner, 1973). The absence of the C8 hydrogen, which 
in adenosine interacts with the furanose ring to decrease rotation, 
combined with this increase in glycosyl bond length, allows for freedom 
of rotation in this adenosine analog not observed in the parent compound. 
Formycin has been shown to be a substrate for P388 murine leukemia adenosine 
deaminase, being deaminated to the inosine analog formycin B (Fig. Ill), 
with a Km and Vmax larger than adenosine (Adamson, 1977) . Adenosine 
deaminase isolated from calf intestines has been shown to accept substrates 
only in the anti conformation and the increased Km observed for formycin 
may be explained by the conformation of this analog which is intermediate 
between syn and anti (Ogilvie, 1971) . Presumably the freedom of rotation 
around the glycosyl bond allows formycin to adopt the anti conformation 
required, and it is subsequently deaminated. The results of Crabtree 
challenge this hypothesis though (Crabtree, 1979). Using N-methylformycins 
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sterically restricted in either the syn or anti conformation as substrates 
for human erythrocyte adenosine deaminase, he demonstrated that this 
enzyme is insensitive to the syn anti conformation variable. Agarwal 
suggests that the increase in Vmax observed for formycin relative to 
adenosine may be accounted for by the N7, N8 diazo bond which would make 
C6 more electropositive and therefore favor nucleophilic displacement 
(Agarwal, 1975). As mentioned earlier, tubercidin was shown by this 
author not to be a substrate for adenosine deaminase. Formycin and 
8-azaadenosine are substrates; however, and it is suggested that the 
imidazole portion of the purine ring of adenine, in particular the N7 
position, appears to be an important structural variable in the activity 
of this enzyme. 
The product of the adenosine deaminase reaction, formycin B, can 
be considered a detoxified product of formycin A. While formycin A was 
shown to have an ID50 of 1.0 uM for L1210 leukemia cells, formycin B 
had an ID50 of 75 uM in this same system (Crabtree, 1979). By adding 
2'deoxycoformycin the percent growth inhibition of P388 murine leukemia 
cells exposed to formycin A was increased from 5% to 71% in the presence 
of this adenosine deaminase inhibitor (Adamson, 1977). These results 
were largely confirmed in viral systems as well where formycin A, but 
not formycin B, were shown to inhibit the multiplication of vesicular 
stomatitis and vaccinia viruses; however, for influenza A virus both 
agents were equally effective in inhibiting multiplication (Takeuchi, 
1966; Giziewicz, 1975). 
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In addition to its cytotoxic effects on P388 and L1210 cells, 
formycin has been shown to be cytotoxic to Yoshida rat sarcoma cells 
and Ehrlich carcinoma cells, cytotoxicity being potentiated in both 
systems by coformycin, another adenosine deaminase inhibitor (Ki human 
-11 
erythrocyte ADA 1 X 10 M Agarwal, 1977). Umazawa demonstrated that 
daily intraperitoneal injections of formycin into mice with ascitic 
Ehrlich ascites carcinoma prolonged the survival of the mice 3 fold, 
and that the same increase in survival could be obtained with a four 
fold lower dose of formycin if coformycin were administered concomitantly 
(Umezawa, 1967). This author further demonstrated that formycin B 
was not cytotoxic to Ehrlich ascites carcinoma cells and that no 
phosphorylated derivitives of this analog could be detected intracellularly, 
unlike formycin A, which was cytotoxic and was found to exist intracellularly 
in mono, di, and triphosphate forms. Further insight into the metabolism 
of formycin was obtained by Sheen who injected mice with formycin and 
found 50% of the injected dose in the urine as oxoformycin (Fig. Ill), 
the xanthosine analog of formycin B (Sheen, 1969). It was demonstrated 
that the conversion of formycin B to oxoformycin was catalized by hepatic 
aldehyde oxidase and that both formycin B and formycin A are competitive 
inhibitors of xanthine oxidase. These results are surprising in lieu 
of the fact that inosine, the structural analog of formycin B, does not 
interact with hepatic aldehyde oxidase, nor does adenosine or inosine 
interact with xanthine oxidase. Oxoformycin has been shown to be 
ineffective as a cytotoxic agent against Yoshida sarcoma cells 
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(Kunimoto, 1968). 
In synchronized cultures of HeLa S3 cells, high concentration 
formycin (10 ug/ml) inhibited DNA synthesis while low dose formycin 
(0.1 ug/ml) inhibited protein synthesis by 25% (Kunimoto, 1967). 
Kunimoto also demonstrated that the cells were sensitive to inhibition 
of cell division by low dose formycin at a stage of early DNA synthesis. 
As mentioned above, DON fibroblasts appeared to be more sensitive 
to the cytotoxic effects of tubercidin at the GIS boundry suggesting 
perhaps a similarity of cell cycle sensitivity to these two agents. 
In discrepancy with these results is the work of Giziewicz who 
showed a 95% reduction in both RNA and DNA synthesis of primary rabbit 
kidney cells exposed to 200 ug/ml formycin, with an 80-90% reduction 
in RNA and DNA synthesis respectively when these cells were exposed to 
40 ug/ml formycin (Giziewicz, 1975). It appears that lower dose formycin 
inhibited RNA synthesis less, and the lack of inhibition of RNA synthesis 
observed by Kunimoto may be explained by an insufficiently broad dose 
response curve. 
As is the case with tubercidin, the biochemical basis for the 
cytotoxicity of formycin has been investigated by numerous authors. 
Formycin was shown not to be incorporated into the nucleotide pool of 
human erythrocytes, where tubercidin was incorporated and converted to 
the triphosphate form (Parks, 1973). This result has not been repeated 
in other systems however. Mouse leukemia EL4 cells exposed to formycin 
were shown to accumulate formycin triphosphate with a dose and time 
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dependent decrease in cellular ATP, though less of a decrease than was 
observed with tubercidin (Zimmerman, 1978). The cyclic analog of formycin 
was also demonstrated. Using intraperitoneal injections of formycin into 
mice carrying a line of ascitic Ehrlich ascites carcinoma cells lacking 
adenosine kinase, formycin was shown to be ineffective against the kinase 
deficient line while inhibiting the parent line by 95% at the same dose 
(Caldwell, 1969). 
That formycin is indeed a substrate for adenosine kinase was 
established using adenosine kinase purified from H.Ep. it2 cells, where 
formycin was found to be phosphorylated at the same rate as adenosine 
(Schnebli, 1967). Further insight into the biochemistry of formycin 
was obtained by Henderson who measured N-formylglycinamide ribonucleotide 
levels in Ehrlich ascites tumor cells exposed to azaserine and formycin 
(Henderson, 1967). In these experiments he demonstrated a 10 fold 
decrease in PRPP synthesis in the parent line as compared to an adenosine 
kinase deficient line. This inhibition of PRPP synthesis, which presumably 
occurs at the level of phosphoribose pyrophosphokinase, was also observed 
in tubercidin treated cells (Henderson, 1965). In addition to inhibiting 
de novo purine biosynthesis, formycin has been shown to decrease 
nucleotide synthesis from hypoxanthine and guanine, but not from adenine, 
in Ehrlich ascites tumor cells (Henderson, 1967). As this author 
suggests, formycin maybe inhibiting HGPRT directly. 
While formycin has not been demonstrated in Vitro or in Vivo to be 
incorporated into DNA, it has been shown to be a substrate for ribonucleotide 
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reductase from Lactobacillus leichmannii where in the absence of dGTP 
formycin simply binds to the active site, while in the presence of dGTP 
it is reduced (Ward, 1969; Brinkley, 1978). With respect to CTP reduction, 
formycin triphosphate was observed to be ineffective as a positive 
allosteric modulator; however, deoxyformycin triphosphate appeared to be 
as effective as dATP and deoxytubercidin triphosphate (Suhadolnik, 1968; 
Brinkley, 1978). 
It appears then that evidence exists that formycin is theoretically 
capable, at least in prokaryotes, to enter the deoxyribonucleotide pool; 
however, unlike tubercidin it has an absolute requirement for the 
binding of dGTP to the allosteric site of ribonucleotide reductase for 
this to occur. Formycin also appears to interact with the allosteric 
site of this enzyme differently than tubercidin, in that only deoxyformycin 
triphosphate is capable of functioning as an allosteric modulator while 
both tubercidin triphosphate and deoxytubercidin triphosphate are effectors. 
As can be seen, both formycin and tubercidin can substitute for 
adenosine as a substrate in numerous enzyme systems. This is not 
universally true however. Unlike tubercidin, which was found to substitute 
for adenosine in nicotinamide adenine dinucleotide (NAD), formycin has 
not been shown to be incorporated into NAD nor was it a substrate for 
purified NAD synthase (Ward, 1969). This author further demonstrated 
that formycin triphosphate could substitute for ATP as an energy source 
for amino acid esterification to tRNA by aminoacyl-tRNA synthase, 
yielding rates of esterification 50%-75% of control depending on the 
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amino acid substrate. On the other hand, tubercidin triphosphate was 
shown to be incapable of serving as an energy source for this enzyme 
(Uretsky, 1968). 
At the level of cellular metabolism concerned with RNA translation, 
both tubercidin triphosphate and formycin triphosphate are utilized by 
tRNA CCA pyrophosphorylase, substituting for adenosine in the 3’ terminal 
CCA group characteristic of tRNA. The tRNAs thus formed are capable 
Phe 
of accepting amino acids, except for tRNA CCTu, which shows a 20 
fold decrease in aminoacetylation with Phe. In addition, these molecules 
appear to vary in their ability to substitute for naturally occurring 
tRNA in cell free systems (Baksht, 1975). With respect to messenger 
function, both tubercidin and formycin substitute for adenosine with 
fidelity; however, polyF does not code for polylysine while polyTu does 
so. Studies on the stimulation of binding of aminoacyl tRNA to ribosomes 
with formycin or tubercidin containing ribonucleotide polymers has 
demonstrated normal to decrease binding for formycin, but normal binding 
for tubercidin (Ikehara, 1965; 1969). In summary, the results of these 
studies seem to suggest that both tubercidin and formycin can substitute 
for adenosine in processes concerned with messenger translation. This 
is an interesting result in lieu of the data presented earlier that 
both compounds inhibited protein synthesis in cytotoxicity studies. 
That the inhibition of protein synthesis results from a derangement 
at the level of RNA transcription is a possibility; however, in mouse 
fibroblasts a simultaneous inhibition of DNA, RNA, and protein synthesis 
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was observed when these cells were exposed to tubercidin (Acs, 1964). 
The rapidity with which tubercidin inhibits protein synthesis would 
suggest that tubercidin in some way directly interferes with RNA 
translation. 
At the level of RNA transcription these analogs appear to behave 
differently when used as substrates by RNA polymerase. While tubercidin 
triphosphate is utilized as a substrate by Mengo virus induced RNA 
polymerase and QB replicase, formycin triphosphate is not (Kapuler, 1969). 
That formycin triphosphate is a substrate for Eh Coli RNA polymerase 
has been demonstrated using numerous templates where the rate of 
polymerization varied from 23%-34% depending on the template (Ward, 1969). 
Slightly higher rates of polymerization of formycin triphosphate were 
observed by Ikehara, 47%-68%, using Eh Coli RNA polymerase and various 
templates (Ikehara, 1968). Acs reported that tubercidin triphosphate 
could be used in homopolymer formation; however, Nishimura, using Eh Coli 
RNA polymerase, demonstrated that the rate of incorporation varied with 
the template and that no homopolymer formation could be detected (Acs, 
1964; Nishimura, 1966). Formycin triphosphate was not used in homopolymer 
synthesis by Eh Coli RNA polymerase (Ward, 1969) . The results of these 
studies are significant in that they indicate that with respect to 
these sterically different adenosine analogs, incorporation into RNA is 
dependent not only on Watson Crick type base pairing, but on the steric 
conformation of the neighboring base as well. 
In rifampicin challenge experiments DNA dependent RNA polymerase 
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from Azotobactor vinelandii initiated chains with tubercidin triphosphate 
at a faster rate than ATP (Kumar, 1977). When formycin triphosphate 
was used as a substrate for chain initiation; however, the tl/2 for this 
reaction was 17X larger than the value for ATP. In phosphodiester bond 
formation formycin triphosphate was far more efficient than tubercidin 
triphosphate in single step addition while in polymerization it performed 
only slightly better. Darlix also observed a decrease in chain initiation 
with normal rates of elongation when formycin triphosphate was used as 
a substrate for E. Coli RNA polymerase (Darlix, 1971). In addition to 
this, he observed that formycin prevented the release of newly synthesized 
RNA chains from the transcription complex. 
It is interesting that these structurally similar adenosine analogs 
would affect different aspects of RNA transcription differently, and 
one can only speculate as to the steric variable that restricts formycin 
in its ability to initiate RNA chains. Kumar concluded that only analogs 
in the anti conformation are suitable substrates for the initiation of 
RNA chains, thereby explaining why tubercidin with a glycosyl torsion 
angle of 73.0 is a better initiator than formycin with an angle of 
109.5 (Abola, 1973; Prusiner, 1973). The situation appears to be more 
complicated than this; however, in that Evans demonstrated that in 
aqueous solution tubercidin, like formycin, exists in syn anti equilibrium 
(Evans, 1975). Whatever the explanation formycin, because of its poor 
ability to initiate RNA chains and its retarding effect on RNA chain 
release, can be expected to disrupt RNA transcription to a significant 
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extent. The effects of formycin on RNA processing will be discussed 
below. 
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8-AZAADENOSINE 
9-8-D-ribofuranosyl-8-aza-adenine is the third adenosine analog 
used in this investigation and unlike the other two compounds, which 
are naturally occurring nucleoside antibiotics, 8-azaadenosine is 
chemically synthesized (Fig. I). Since its first reported synthesis 
in 1958, not much data has been accumulated on the mechanism of action 
of this triazolo adenosine analog (Davoll, 1958). It belongs to the 
general category of 8-azapurine nucleosides such as formycin and 
8-azaguanosine, and like formycin and tubercidin exists in an intermediate 
anti syn conformation with a glycosyl torsion angle of 103.6, very 
similar to the angle of formycin (Singh, 1974; 1977). Unlike formycin 
which has an increased glycosyl bond length, the glycosyl bond of 
8-azaadenosine is 0.02 A shorter than adenosine. The replacement of 
C8 with nitrogen not only distorts the angles of the imidazole moiety 
of the parent compound, and provides an additional basic site, but makes 
C6 more electropositive as in the case of formycin. This variable, as 
well as the syn anti conformation of 8-azaadenosine, is used to explain 
the higher Km and Vmax when compared to adenosine using purified human 
erythrocyte adenosine deaminase (Agarwal, 1975). Since tubercidin is 
not a substrate, these authors concluded that N7 is important in substrate 
binding; however, in 8-azaadenosine N7 is not protonated and therefore 
unavailable for hydrogen bonding (Singh, 1974) . Taken together this 
would imply that N7 may be important in functioning in activities other 
than hydrogen bonding. 
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Similar results were obtained with adenosine deaminase isolated from 
P388 murine leukemia cells, and in one experiment percent growth inhibition 
was increased from 13% to 57% in the presence of dCF (Adamson, 1977). 
In addition to adenosine deaminase, 8-azaadenosine has been shown 
to be a substrate for purified adenosine kinase from H.Ep. #2 cells, 
being phosphorylated 1.9X faster than adenosine (Schnebli, 1967). 
3 
Using these same cells in culture [H ] 8-azaadenosine was found to be 
converted to mono, di, and triphosphate forms (Allan, 1972). In 
human erythrocytes 8-azaadenosine was found to be incorporated as the 
monophosphate only (Parks, 1973). 
Antitumor activity of 8-azaadenosine has been demonstrated using L1210 
and P388 murine leukemia cells where mice carrying these tumors intraperitoneally 
had a percent increase in life span of 42% and 70% respectively when 
treated with 8-azaadenosine (Montgomery, 1975). The mechanism of 
this cytotoxicity is difficult to elucidate in that unlike tubercidin 
and formycin, which are not metabolized to other potent antineoplastic 
agents, 8-azaadenosine is. As early as 1957 it was recognized that 
8-azaadenine inhibited the growth of tobacco mosaic virus and _E. Coli 
(Smith, 1957). Smith suggested that this inhibition was correlated with 
the incorporation of 8-azaguanine into RNA by showing that no 8-azaadenine 
could be detected in the alkaline hydrolizates of the RNA. In H.Ep. #2 
cells 8-azaadenosine was found to be 20X more toxic than its aglycone, 
implying low conversion of this substrate by APRT (Montgomery, 1975). 
A subline of these cells deficient in adenosine kinase, and another 
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subline with a combined deficiency in adenosine kinase and APRT, were 
both shown to have the same degree of resistance to 8-azaadenosine 
implying that this substrate is being metabolized via pathway III in 
(Fig. II) to account for its cytotoxic effects (Bennett, 1966). Further 
elucidation of this mechanism was obtained using a line of cells with 
a combined deficiency of adenosine kinase and HGPRT where the degree of 
resistance rose to approximately 30X the resistance demonstrated in the 
two sublines mentioned previously (Montgomery, 1975). Since this 
adenosine kinase HGPRT deficient subline was similarly resistant to 
8-azainosine, these authors concluded that the mechanism of cytotoxicity 
of 8-azaadenosine resided in its ability to be metabolized to 8-azainosine. 
A similar proposal had been made 3 years earlier by Allen who demonstrated 
3 
that [ H] 8-azaadenosine was converted by the parent line of H.Ep. #2 
cells to 8-azaAMP, 8-azaADP, 8-azaATP, as well as small amounts of 
8-azaIMP (Allan, 1972). When a subline deficient in adenosine kinase 
3 
and APRT was incubated with [ H] 8-azaadenosine, only a small quantity 
of 8-azaIMP could be detected, yet 8-azaadenosine was equally cytotoxic 
to both cell lines. The authors concluded that it was 8-azaIMP that 
was the cytotoxic end product of 8-azaadenosine metabolism. Further 
insight into these cytotoxic metabolites was obtained by Bennett who 
demonstrated that 8-azainosine increased the life span of mice carrying 
intraperitoneal L1210 leukemia cells by 40%-50%, and that this compound 
was equally effective against a line lacking HGPRT and therefore 
resistant to 8-azahypoxanthine (Bennett, 1973). Similar results have 
23 

also been obtained by Bennett using H.Ep. #2 cells in culture and 
confirmed by Montgomery (Montgomery, 1975). These data imply the 
existence of an inosine kinase as an alternative route of inosine 
metabolism. When H.Ep. #2 cells were treated with 8-azainosine the 
degree of resistance was observed to increase 20 to 40 fold in a subline 
with a combined deficiency in adenosine kinase and HGPRT, as compared 
to a subline lacking HGPRT alone (Montgomery, 1975). These authors 
concluded that either 8-azainosine is a substrate for adenosine kinase 
or that a closely linked inosine kinase was subsequently lost when the 
adenosine kinase deficient line was selected for. Similar results were 
obtained by Bennett to explain the cytotoxicity of 7 deazainosine in 
these same sublines (Bennett, 1966). Subsequent studies demonstrated 
14 
that while [ C ] 8-azainosine was converted almost exclusively to 
14 
8-azaguanine nucleotides by H.Ep. #2 cells, [ C] 8-azaadenosine was 
converted to the nucleotides of adenine and guanine equally (Bennett, 
1976). Similar results are obtained when incorporation into polynucleo¬ 
tides (DNA + RNA) were examined. 8-azaadenosine treated cells showed 
equal incorporation of adenine and guanine nucleotides, while 8-azainosine 
treated cells showed exclusive incorporation as 8-azaguanine. In a 
H.Ep. #2 subline lacking adenosine kinase and APRT, both 8-azaadenosine 
and 8-azainosine treated cells demonstrated approximately 90% incorporation 
into polynucleotides as 8-azaguanine. The authors concluded that 
8-azaIMP is a substrate for IMP dehydrogenase and GMP synthase, but it 
is not used by the enzymes in the anabolic pathway from IMP to AMP. In 
addition to this; however, one can conclude that the 50% incorporation of 
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adenine observed in the parent line treated with 8-azaadenosine is due 
to metabolism by adenosine kinase or APRT. Considering the low toxicity 
of 8-azaadenine mentioned earlier it can be concluded that pathway I 
in (Fig. II), which utilizes adenosine kinase, shares equally with 
pathway III the metabolism of 8-azaadenosine. When a subline of the 
H.Ep. #2 cells resistant to 8-azainosine but sensitive to 8-azaadenosine 
was treated with 8-azaadenosine, 90% incorporation as adenine was 
observed in the polynucleotide fraction. This line was shown not to 
be deficient in adenosine kinase or HGPRT; however, it did show an 
approximately 50% reduction in the ability to convert 8-azainosine to 
8-azahypoxanthine (Bennett, 1973). This data becomes interpretable 
if one assumes a concomitant deficiency in inosine kinase, thereby 
leaving only the adenosine kinase pathway accessible for the metabolism 
of the 8-azaadenosine, and no pathway accessible for the metabolism of 
8-azainosine in this 8-azainosine deficient line. 
In summary, the cytotoxicity of 8-azainosine may be linked to its 
incorporation into DNA and RNA as 8-azaguanine. While Bennett did not 
further define the incorporation into DNA vs RNA, the majority of 
8-azaguanine is most likely incorporated into RNA since negligible 
amounts of 8-azaguanine has been noted to be incorporated into DNA in 
other systems (Parks, 1974). The basis of the cytotoxicity of 
8-azaadenosine may also be linked to its incorporation into DNA and RNA 
as observed in the 8-azainosine resistant subline. In the parent line; 
however, one cannot conclude that cytotoxicity is attributable tc 
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8-azaadenosine alone since extensive conversion to 8-azaguanine metabolites 
also occurs. It is interesting in this regard that Adamson observed an 
increase in cytotoxicity of 8-azaadenosine to P388 leukemia cells when 
these cells were also treated with dCF. dCF, by inhibiting adenosine 
deaminase, would be expected to block conversion of 8-azaadenosine to 
8-azaguanosine. 
Like tubercidin and formycin, 8-azaadenosine has been shown to be 
a feedback inhibitor of de novo purine biosynthesis in azaserine treated 
H.Ep. #2 cells (Bennett, 1964). It is not known; however, if this in¬ 
hibition occurs at the level of amidophosphoribosyl transferase or 
phosphoribose pyrophosphokinase, as was observed for tubercidin and 
formycin (Henderson, 1965; 1967). 
In the preceding sections the cellular metabolism of the three 
antitumor agents tubercidin, formycin, and 8-azaadenosine has been 
reviewed. While these compounds are dissimilar only in that they vary 
in the imidazole portion of the purine ring of the parent compound 
adenosine, these subtle steric differences are responsible for their 
biochemical properties and ultimately their cytotoxic potential. In 
the next section evidence will be presented that these compounds disrupt 
RNA processing, and that their ability to interfere with the methylation 
of RNA may be a mechanism by which this occurs. 
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-PART TWO- 
METHYLATION AND EUCARYOTIC RNA PROCESSING 
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In this section the role of methylation in eucaryotic RNA processing 
will be briefly reviewed. 
HETEROGENEOUS NUCLEAR AND MESSENGER RNA 
The process begins with RNA transcription and in eucaryotes three 
RNA polymerases have been identified based on their different sensitivities 
to the inhibitor a-amanitin, isolated from the poisonous mushroom Amanita 
phalloides. In animal cells RNA polymerase II is the most sensitive 
and it is this polymerase that generates heterogeneous nuclear RNA (hnRNA). 
As has been reviewed by Lewin, the majority of radioactive label incorporated 
into hnRNA turns over in the nucleus, implying extensive intranuclear 
degradation of this molecule (Lewin, 1980). Heterogeneous nuclear RNA 
has an average length of 8000-10,000 bases and presumably is the precursor 
of mRNA, which has an average length of 2000-2100 nucleotides, as suggested 
by pulse chase experiments whereby the 3’ terminal poly A and 5' methyl 
caps of hnRNA have been shown to be conserved in mRNA. The function of 
these terminal modifications remains obscure but it has been suggested 
that they may play some role in message selection from the large pool 
of hnRNA precursors. Only 70% of mRNA from HeLa cells is poly adenylated, 
specifically histone mRNA has been shown to lack a poly A tail, arguing 
against the necessity of a poly A tail for message transport. 5’ methyl 
caps have been shown to be more ubiquitous with only certain viruses 
such as polio, encephalomyocarditis, tobacco necrosis, satellite tobacco 
necrosis virus, and yeast killer particle RNA lacking caps (Muthukrishnan, 
1978). Transfer RNA (tRNA) and ribosomal RNA (rRNA) also lack caps 
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but are transported to the cytoplasm, again demonstrating that terminal 
modification is not required for message transport. 
As can be seen in (Fig. IV), the 5' cap consists of a 7-methyl-guanosine 
linked by a 5'-5' pyrophosphate bridge to a 2’-0-ribose methylated base. 
This structure is designated as cap 1, and while all the caps of hnRNA 
are of this type, only 65% of the caps on messenger RNA are cap 1 (Cori, 
1975). Twenty percent of mRNA caps contain adenosine in the second 
position which is further methylated at N^ to generate dimethyl (2'-0; N^) 
adenosine. The remaining 15% of 5' terminal caps of mRNA are designated 
as cap 2, where the third base from the 5’ end is additionally methylated 
at the 2'-0-ribose position. 
The putative mechanism for the generation of these caps is summarized 
in (Fig. V) where the capping reaction is believed to occur after the 
initiation of transcription; however, in cytoplasmic polyhedrosis 
virus evidence has been obtained suggesting that cap formation may occur 
as early as the initiation step (Furuichi, 1979). Similar evidence 
exists for reovirus and possibly vaccinia virus as well (Shatkin, 1976). 
Following initiation with a purine nucleoside, guanine is added via 
guanyl transferase and is subsequently methylated to 7-methylguanine 
by 7-methyltransferase with S-adenosylmethionine (SAM) as a methyl 
donor. Next, 2'-0-methyl transferase utilizes SAM to methylate the 
ribose of the second base, which for mRNA 64% of bases analyzed is a 
purine. Since transcription is initiated with a purine, this implies 
that at least 36% of caps are generated from internally cleaved precursors. 
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For those caps having N , 2'-O-dimethyladenosine, the base methylation 
reaction has been shown to follow the 2'-0-ribose modification (Keith, 
1978). This enzyme is specific for the cap structure and is not believed 
to be involved in the generation of internal N^-methyl adenosine residues. 
As appears to be the case for transmethylation reactions in general, 
these methyl transferases are inhibited by S-adenosylhomocysteine (SAH), 
the product of SAM coupled transmethylations (Coward, 1973). 
As reviewed by Shatkin, the 5' terminal cap appears to protect RNA 
from degradation thereby influencing message turnover (Shatkin, 1979). 
In addition to this, several studies have indicated that the cap structure 
is important in the efficient translation of message. Vaccinia virus 
mRNA with an unmethylated 5' terminal guanosine was shown to have 
decreased binding to ribosomes, as well as poor ability to stimulate 
protein synthesis, in wheat germ or rabbit reticulocyte lysate systems 
(Muthukrishnan, 1976). Restoration of ribosome binding capacity and 
message function were observed when guanine 7-methyltransferase was 
used to remethylate the terminal base. These authors also demonstrated 
that 2'-O-methylation has significantly less influence on ribosome 
binding under the in Vitro conditions used. Similar results were 
obtained from studies on the binding of cap modified vesicular stomatitis 
virus mRNA, reovirus mRNA, and capped synthetic ribopoymers to rabbit 
reticulocyte or wheat germ ribosomes (Muthukrishnan, 1976). By using 
an RNA (2'-O-methyladenosine-N^)-methyltransferase isolated from HeLa 
cells to generate a dimethyladenosine cap 1 structure on vaccinia virus 
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mRNA, Muthukrishnan showed that this base modification did not increase 
the ribosome binding capacity of this mRNA as compared to unmodified 
cap 1 containing vaccinia mRNA. From these studies it can be concluded 
that base methylation of the terminal guanosine in the 5' terminal 
caps of RNA has profound effects on ribosome binding, where 2’-0-ribose 
methylation and additional base methylations contribute minimally to 
this reaction, at least under the in Vitro conditions examined. 
In addition to the methylated nucleosides found in the 5* terminal 
caps of both hnRNA and mRNA, both of these molecules contain internal 
m^A and small amounts of m^C, except for HeLa histone and globin mRNA 
(Moss, 1977; Perry, 1975). m^A appears to be distributed in the 
ms ms 
trinucleotides GA C (70%) and AA C (30%) both in hnRNA and mRNA from 
HeLa and L cells (Wei, 1977; Schibler, 1977). This similar distribution 
of N^ methyl adenosine in both hnRNA and mRNA, combined with the 
observation that an increase to 1.0 m^A/1000 bases of mRNA from 0.4 
m^A/1000 bases of hnRNA occurs, is taken as evidence for the precursor 
product relationship of hnRNA to mRNA, and that internal methylations 
may be involved in this process. 
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RIBOSOMAL RNA 
Another example of conserved internally methylated bases in RNA 
maturation is ribosomal RNA processing (Fig. VI). In eucaryotes RNA 
polymerase I transcribes a 45s precursor rRNA molecule from clusters 
of tandemly repeated ribosomal genes in the nucleolus. This precursor 
molecule contains the sequences of 18s rRNA, which is present in the 
40s ribosomal subunit, as well as the 5.8s and 28s rRNA sequences which 
are found in the 60s ribosomal subunit. The 5s rRNA of the 60s ribosomal 
subunit is transcribed at a separate locus by RNA polymerase III. 
As has been extensively reviewed, HeLA cell 18s rRNA contains 45 
methyl groups, 7 of which are base methylations. 28s rRNA has 68 
methylated groups, 5 of which are base methylations, and 5.8s rRNA 
contains 1 and possibly 2 methyl groups (Burdon, 1971; Maden, 1979; 
Lewis, 1980). As can be seen the majority, approximately 90% of the 
110-115 total methylated nucleotides, are methylated at the 2' hydroxyl 
position of the ri'bose. These sugar methylations are believed to occur 
rapidly after transcription while the base modifications which include 
6 6 
l-methyladenine, N -methyladenine, N -dimethyladenine, 1-methylguanine, 
7 2 
N -methylguanine, N -dimethylguanine, 7-methylguanine, 3-methylcytosine, 
and 3-methyluracil, are believed to occur later. 5s rRNA is unmethylated. 
3 32 
Using [ H ] methionine and [ P] phosphate to label the RNA of HeLa 
cells infected with polio virus, which causes an accumulation of ribosomal 
RNA intermediates, Weinberg elucidated the maturation pathway in (Fig. VI) 
(Weinberg, 1970). The 45s precursor is entirely methylated except for 
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two adjacent dimethyladenosines, which later appear in the 18s species. 
This precursor gives rise to a 41s intermediate, which is then cleaved 
to a 32s and 20s fragment. The 20s species is further processed to 18s 
rRNA, while the 32s fragment goes on to 28s and 5.8 s rRNA. By showing 
3 32 
that the ratio of [ H ] methyl groups to [ P] labeled nucleotides 
increased during the maturation process, Weinberg was able to demonstrate 
that the sequences lost were unmethylated and that the methyl groups 
on the original 45s precursor transcript were preserved quantitatively. 
As it turns out, roughly 50% of the 13,000 nucleotides in the original 
45s precursor are the unmethylated G-C rich transcribed spacers, later 
to be discarded in the maturation process. 
That methylation is important in this maturation scheme is suggested 
by the results of methionine deprivation experiments in HeLa cells 
(Vaughan, 1967). HeLa cells deprived of methionine but not valine 
continue to transcribe the 45s precursor and process it to the 32s 
intermediate, despite the fact that there are 5X and 3X fewer 
2'-0-ribose methylations respectively. No further processing was 
observed in the methionine deprived cells, and in fact, further intermediates 
14 
were shown to be degraded. By adding back [ C] methionine, after 
treating the cells with actinomycin D to block further transcription, 
Vaughan showed that label entered the 45s and 32s rRNA species and could 
be detected in ribosomal RNA isolated from the cytoplasm. He concluded 
that methylating enzymes recognize specific sites independent of the 
length of the molecule or its stage in maturation. 
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It is true that all the methylated sites possess different primary 
sequences, but as Maden points out, this would require separate methylating 
enzymes for each sequence leading to a highly complex scheme (Maden, 1974). 
He suggests that the functional role of 2'-O-methylation is to protect 
against nucleolytic degradation, and therefore only exposed sequences 
would be methylated at the 2' hydroxyl position by enzymes recognizing 
this conformational feature. Using nuclease S , which hydrolyzes single 
stranded regions in the nucleic acids, this conformational hypothesis 
was tested for HeLa cell 18s rRNA (Khan, 1978) . The results indicated 
that it was the four base methylated sites, modified late in maturation, 
that were accessible to nuclease S^, and therefore exposed, with less 
than 50% of the sites carrying 2'-0-ribose methyl groups in exposed 
positions. The unexposed methylated sites were presumably modified 
early in the maturation process by methylating enzymes that apparently 
recognize primary sequence, later to be burried by secondary and tertiary 
interactions. 
As can be seen, ribosomal RNA maturation is a process that conserves 
methylated nucleotides. Whether these methylated bases provide specific 
recognition sites for the ribonucleases involved in this process, or 
simply protect the various intermediates from degradation remains to 
be elucidated. 
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TRANSFER RNA 
Transfer RNA is the transcription product of RNA polymerase III, 
and while being only 73-93 nucleotides in length, it is the most highly 
modified nucleic acid in cells (for reviews see Burdon, 1971; Nau, 1976; 
and Smith, 1976). The familiar cloverleaf structure of tRNA is 
depicted in (Fig. VII) with the amino acid arm, the anticodon arm, extra 
arm if present, and the Tip (pseudouridine) C arms representing the leaves 
of the cloverleaf. On the average there are 6 to 7 methylated nucleo¬ 
tides/ tRNA in eucaryotes and unlike rRNA, ribose methylation accounts 
for only 10%-20% of the total methylation. The species of methylated 
bases identified in the tRNA of HeLa and mouse cells include 
2 .22 
1-methyladenine, 1-methylguanine, N -methylguanine, N , N -dimethylguanine, 
7-methylguanine, 5-methylcytosine, and 5-methyluracil with 1-methylhypo- 
xanthine, 3-methylcytosine, and 3-methyluracil occurring in minor amounts. 
Unlike ribosomal RNA maturation, the role of methylated nucleotides 
14 
in tRNA processing is obscure. Using [ C] uridine to label the small 
RNA of HeLa cells, radioactivity was found to be incorporated into 
material migrating between 5s ribosomal and 4s tRNA (Bernhardt, 1969) . 
In actinomycin D block pulse chase experiments, label in this putative 
4.5s pre-tRNA was chased into tRNA and further experiments demonstrated 
14 
that both pre-tRNA and tRNA incorporated [ C] methylmethionine. A 
possible role for methylation in this maturation process was suggested 
by methionine starvation experiments where HeLa cells deprived of 
methionine were shown to have a decreased rate of conversion of pre-tRNA 
35 

to tRNA, as well as a decreased rate of synthesis of the precursor. 
Addition of methionine, but not vlaine, restored to normal levels the 
rate of conversion of the precursor tRNA to its mature form. Bernhardt 
also noted that the undermethylated tRNA produced accumulated in the 
cytoplasm, and he concluded that complete methylation is not essential 
for tRNA maturation. 
Since this early observation, 4.5s pre-tRNA has been observed 
in numerous systems including Chinese hamster ovary and Ehrlich ascites 
tumor cells (Choe, 1972). Analogous to the ribosomal RNA precursor, 
pre-tRNA from yeast has been shown to contain intervening sequences 
which are subsequently removed in the maturation process (Knapp, 1978). 
The location of the maturation events is also a subject of debate; 
however, in experiments with HeLa cells a crude cytoplasmic extract 
was shown to convert pre-tRNA to tRNA suggesting that the cytoplasm 
is the locus of tRNA processing (Bernhardt-Mowshowitz, 1970) . 
Further insight into the relationship between methylation and 
tRNA processing was obtained by Munns (1975) . Using human carcinoma 
KB cells in labeled methionine pulse chase experiments, Munns was able 
to determine specific methylation events as a function of tRNA 
maturation by varying the time of the initiation of the pulse relative 
to the actinomycin D block. The results indicated that late stage 
2 
methylations included 2'-0-methylribose, N -methylguanine, and 
3-methylcytosine. Intermediate stage modifications included 1-methyladenine, 
5-methylcytosine, and 5-methyluracil while the early methylated nucleotides 
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were 1-methylguanine, 7-methylguanine, and N , N -dimethylguanine. As 
was pointed out, the late modifications appear restricted to the anticodon 
loop and the dihydrouridine arm, while the intermediate stage methylated 
nucleotides are found in the TipC loop and arm. Early methylated nucleo¬ 
tides appear to reside around the junctions of the major arms (Fig. VII). 
Munns concluded that selected regions of tRNA become methylated at 
specific times during the maturation of pre-tRNA. 
The enzymes responsible for the generation of these methylated 
nucleotides, the S-adenosylmethionine tRNA methyltransferases, are 
a group of "base specific, species specific, and organ specific" enzymes 
that in eucaryotes specifically require S-adenosylmethionine (SAM) as 
a methyl group donor (Kerr, 1972). They are highly sensitive to 
competitive inhibition by the product of the transmethylation reaction, 
—S 
S-adenosylhomocysteine (SAH), with Ki values ranging from 6.3 X 10 M 
to 2 X 10 for various enzymes (Nau, 1976) . The cellular location 
of these enzymes is not known with certainty. Cell fractionation 
techniques using Krebbs II mouse ascites cells located these enzymes 
predominately in the cytoplasm (Burdon, 1967). Similar results were 
obtained in rat liver cells using in Vivo labeling techniques 
(Muranatsu, 1968). As Burdon points out; however, aqueous media was 
used in the cell fractionation procedures and the possibility therefore 
exists that the methylating enzymes were extracted from the nuclei during 
isolation. The majority of tRNA methylase activity has been reported 
to be associated with nuclei when non-aqueous media was used (Kahle, 1971). 
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While numerous studies have demonstrated that the tRNA methyl- 
transferases are a group of tRNA specific, base and base position 
specific enzymes, Nau suggests that they can be divided into two 
general categories. The "common methylases" are responsible for the 
modification of those bases at sites that are found to be methylated 
on many different tRNA species such as 2'-O-methylguanosine #19, 7-methyl- 
guanosine #55, 5-methyl uridine #70, and in eucaryotes additionally 
2 2 2 
1-methylguanosine #9, N -methylguanosine #10, N , N -dimethylguanosine 
#29, 5-methylcytidine #64 and #65, and 1-methyladenosine #74. "Specific 
methylases" would be responsible for the generation of the pattern of 
methylation distinctive of each tRNA species. 
The biologic role of methylated bases in tRNA remains obscure. 
Although the experiments by Bernhardt mentioned previously would seem 
to indicate that complete methylation is not critical for tRNA 
maturation, certain key methylations may in fact be important in this 
process. The data obtained by Munns showing that specific methylations 
occur in a time ordered sequence of pre-tRNA maturation supports this 
point of view. That methylated nucleotides are important in establishing 
and maintaining the unique tertiary structure of tRNA has been proposed, 
and in support of this is the observation that the majority of methylated 
2 2 
nucleotides occur in non-base paired regions. Only N , N -dimethylguanosine 
and 5-methylcytosine, which do not prevent G-C hydrogen bonding, are 
found in helical regions. To date however, a specific functional role 
of methylated nucleotides in tRNA has not been unambiguously assigned. 
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RNA PROCESSING IN DRUG TREATED CELLS 
Earlier in this section the maturation of various species of RNA 
in eucaryotes was reviewed, and experimental evidence suggesting that 
methylated nucleotides are important in RNA processing was examined. 
Tubercidin and formycin have been demonstrated by several authors to 
disrupt RNA processing. Polyacrylamide agarose gel electrophoresis of 
total cellular RNA isolated from Novikoff hepatoma cells exposed to 
1 ug/ml tubercidin for 2 hours showed approximately 80% inhibition of 
3 
incorporation of [ H] uridine into 32s rRNA, with greater than 95% 
inhibition of incorporation of label into 28s and 18s rRNA as compared 
3 
to control (Weiss, 1974). Incorporation of f H] uridine into 45s and 
38s rRNA was the same in control and treated cells. (Novikoff hepatoma 
38s rRNA is similar to the 41s rRNA precursor of HeLa cells.) L5178Y 
mouse tumor cells treated with 0.05 ug/ml tubericdin for 6 hours were 
shown by similar analytic techniques to contain a "high molecular 
weight precursor RNA" not isolated from control cells (Seibert, 1978). 
Although this material was not characterized, it seems possible that it 
may be high molecular weight precursor rRNA. These authors further 
demonstrated that tubercidin treated cells contained decreased amounts 
of 4s and 5s RNA as compared to untreated cells. 
Interference with ribosomal RNA processing has also been observed 
with formycin. HeLa cells treated with 25 ug/ml of formycin for 10 
3 
minutes followed by a 90 minute pulse of [ H] uridine exhibited delayed 
processing of 45s rRNA to 32s rRNA (Abelson, 1973). With a 30 minute 
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[ H] uridine pulse followed by actinomycin D to block transcription and 
allow processing of pre-tRNA to the mature 4s form, these authors also 
demonstrated that cells treated with formycin showed significant inhibition 
of cytoplasmic 4s and 5s RNA at a concentration of drug not affecting 
the synthesis of hnRNA or 45s ribosomal precursor. This differential 
inhibition of low molecular weight RNA synthesis was also observed in 
formycin treated posterior silk glands of the silk worm Bombyx mori 
3 
(Majima, 1977). Using pulse chase experiments with [ H] uridine, these 
authors made the important observation that the conversion of 4.5s 
pre-tRNA to tRNA was significantly inhibited in formycin treated glands, 
while the rate of incorporation of label into pre-tRNA and the disappearance 
of pre-tRNA was the same as control. Glands exposed to [ ^C] formycin 
were shown to incorporate formycin into total RNA as well as pre-tRNA, 
but only negligibly into 4s RNA. The authors concluded that formycin 
containing precursor tRNA was degraded by a scavenger mechanism, and 
in a subsequent study when formycin containing pre-tRNA was incubated 
with a crude ribosomal wash from the silk glands, no 4s RNA was observed 
to accumulate (Tsutsumi, 1978). 4.5s precursor tRNA isolated from 
control cells was converted to 4s material by this extract. 
In summary, the above experiments suggest that formycin inhibits 
ribosomal as well as tRNA processing from their respective precursors. 
Tubercidin likewise inhibits ribosomal RNA maturation, and although 
tubercidin triphosphate was shown by Seibert to inhibit DNA dependent 
RNA polymerases I, II, and III isolated from mouse liver (Seibert, 1978), 
the studies by Majima and Tsutsumi cast doubt on the hypothesis that 
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inhibition of RNA transcription can be used solely to explain the 
decreased amounts of cytoplasmic 4s RNA observed in the tubercidin 
treated cells. 
As mentioned in the previous section, HeLa cells deprived of 
methionine were shown to contain undermethylated precursor ribosomal 
RNAs that did not complete maturation due to degradation of further 
intermediates (Vaughan, 1967). Similarly, methionine starved HeLa cells 
demonstrated a decreased rate of conversion of pre-tRNA to tRNA 
(Bernhardt, 1969). Although Weiss, Majima, and Tsutsumi proposed that 
the mechanism of the interference in RNA maturation in tubercidin and 
formycin treated cells was due to incorporation of these analogs into 
RNA leading to molecules with anomalous properties, when considered 
in light of the methionine deprivation experiments another mechanism 
becomes plausible whereby these drugs interfere with RNA methylation, 
and it is the generation of improperly methylated precursors that 
accounts for the inhibition of RNA processing observed. Evidence does 
in fact exist that these analogs, as well as 8-azaadenine, can inhibit 
various tRNA methylases in Vitro, albeit at very high concentrations. 
Using submethylated tRNA and enzyme extracts from E. Coli, 
lumole/ml 8-azaadenine was shown to inhibit tRNA methylation by 10% 
(Moore, 1970). Tubercidin, in concentrations ranging from approximately 
300 to 400 ug/ml inhibited tRNA methylation in crude enzyme extracts 
of calf liver, E. Coli, and calf spleen by 19%, 24%, and 30% respectively 
(Wainfan, 1967). More specifically, tubercidin was shown to inhibit 
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guanine tRNA methyltransferases from E. Coli, and when uracil tRNA 
methyltransferase was examined approximately 1 mM tubercidin inhibited 
this enzyme by 44%, while at a similar concentration formycin inhibited 
this enzyme by only 2% (Wainfan, 1975). 
It can be seen that the evidence that these adenosine analogs can 
interfere with RNA methylation is restricted to in Vitro studies, mostly 
with procaryotic tRNA methyltransferases and at very high concentrations 
of inhibitor. The present study was designed to investigate the effects 
of tubercidin, formycin, and 8-azaadenosine on the synthesis and 
methylation of nuclear RNA in L1210 mouse leukemia cells. Because these 
adenosine analogs are dissimilar only in that they vary in the imidazole 
portion of the purine ring of the parent compound, it is hoped that 
specific structure activity correlates can be deduced. 
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-PART THREE- 
THE EFFECTS OF TUBERCIDIN, 8-AZAADENOSINE, AND FORMYCIN ON THE 
SYNTHESIS AND METHYLATION OF NUCLEAR RNA IN L1210 
MOUSE LEUKEMIA CELLS 
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ABBREVIATIONS: 
nRNA, nuclear RNA; SDS, sodium dodecylsulfate; TCA, trichloroacetic acid; 
dCF, 2'-deoxycoformycin [(R)-3-(2-deoxy-B-D-erythropentofuranosyl)-3,6,7,8- 
tetrahydroimidazo [5,4-d] [1,3] diazepin-8-ol], m^A, 1-methyl-adenosine; 
3 5 1 
m C, 3-methylcytidine; m C, 5-methylcytidine; m G, 1-methylguanosine; 
2 2 2 2 2 7 
m G, N -methylguanosine; m^G, N , N -dimethy1guanosine; m G, 7-methyl- 
guanosine; m^U, 5-methyluridine; IC^, median inhibitory concentration. 
MATERIALS AND METHODS: 
Materials: Tubercidin, 8-azaadenosine, formycin, and dCF were obtained 
from the Drug Synthesis and Chemistry Branch, National Cancer Institute. 
3 3 [5- H-methyl] Thymidine (20Ci/mmole), L-[methyl- H] methionine (80Ci/mmole), 
14 
and [U- C] uridine (464 mCi/mmole) were purchased from the New England 
13 5 12 
Nuclear Corporation, Boston, Massachusetts, m A, m C, m C, M G, M G, 
2 7 5 
M^G, m G, and m U were obtained from P-L Biochemicals, Milwaukee, Wisconsin. 
Animals: L1210 cells were inoculated, i.p., into BALB/c X DBA/2 F^ mice 
at an inoculum of 10~* cells/0.1 ml Hanks’ balanced salt solution. Cells 
were harvested 6 days after inoculation and were further diluted with 
incubation medium. 
Incubations: Incubations of L1210 cells were carried out at 37° in a 
shaking water bath at 100 r.p.m. and consisted of: (1) 25 ml of 
7 3 
L-methionine-free RPMI 1630 medium, 5 X 10 cells, 200uCi [ H] methionine 
(80 Ci/mmole) and 5 uCi [^c] uridine (464 mC /mmole) or (2) 5 ml of 
RPMI 1630 medium, 1 X 10^ cells, luCi [^C] uridine (464mCi/mmole) and 
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3 
5 uCi ( H] thymidine (20 Ci/mmole). Cells were preincubated with luM 
dCF for 15 minutes before further incubation for 30 minutes with either 
tubercidin, 8-azaadenosine, or formycin. The period of labeling was 1 hour. 
14 3 
Total RNA and DNA Synthesis: Incorporation of [ C] uridine and [ H] 
thymidine into total RNA and DNA respectively was measured by cooling 
the incubation flasks on ice for 15 minutes and adding ice-cold TCA to a 
final concentration of 10% (w/v). Precipitates were collected on glass 
fiber filter discs, washed 3X with 5% TCA and 2X with 95% ethanol. Discs 
were dried and counted in 10 ml Aquasol in a Searle Mark III liquid 
scintillation system. 
RNA Extraction: After incubation, cells were centrifuged at 400g for 20 
minutes at 4° C, washed once with cold RPMI 1630 medium, and recentrifuged 
at 400 g for an additional 10 minutes at 4° C. Nuclei were prepared from 
the cell pellet by resuspension in 10 ml of lOmM magnesium acetate swelling 
medium (pH 5.1) for 15 minutes at 4° C. This swelling medium was 
previously found to markedly inhibit the activity of intracellular RNase, 
thereby minimizing the hydrolysis of nRNA before extraction. The samples 
were then adjusted to room temperature by stirring for 10 minutes at room 
temperature, followed by the addition of 0.15 ml of Triton X-100 for an addi¬ 
tional 5 minutes. Nuclei were collected by centrifugation at 2000 g for 
10 minutes at 4° C and resuspended in 5 ml of 0.34 M sucrose, 5mM magnesium 
chloride which was layered on a cushion of 5 ml of 0.88 M sucrose, 5 
mM magnesium chloride, and centrifuged at 2000g for 10 minutes at 4°C. 
nRNA was extracted from the pelleted nuclei by vortexing vigorously for 
2 minutes with 3 ml of 0.1% SDS: 0.14M NaCl: 0.025M sodium acetate 
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(pH 5.1) and 3 ml of phenol mixture (phenol-m-cresol-water (7:2:2), v/v) 
containing 0.1% 8-hydroxyquinoline. The emulsion was clarified by 
centrifugation at 12,000g for 10 minutes, and the upper aqueous phase 
was removed and precipitated with 3 vol. of 2% potassium acetate in 95% 
ethanol at -20°C overnight. 
DEAE Sephadex-Urea Chromatography: precipitated RNA was collected by 
centrifugation at 10,000g for 20 minutes at -10° C. The precipitate 
was washed with cold 95% ethanol and recentrifuged at 10,000g for 
10 minutes at -10° C. The pelleted RNA was hydrolyzed at 37° C 
overnight in 0.5 ml of 0.3 N potassium hydroxide. Phenolphthalein was 
added as an indicator and the pH adjusted with perchloric acid till 
slightly basic. The samples were allowed to stand on ice for 20 
minutes followed by centrifugation at 2000g for 10 minutes at 4° C 
to remove the potassium perchlorate precipitate. The supernatant 
was diluted to 10 ml in buffer: 20mM Tris HCl (pH 7.6), 7 M urea 
and absorbed onto a 0.9 cm X 15 cm column of DEAE sephadex equilibrated 
in buffer. The column was washed with 10 ml of buffer and eluted with 
a 200 ml linear gradient of 0.1 M NaCl to 0.7 M NaCl 2 ml fractions 
were collected, mixed with 15 ml of Hydroflour, and counted in a Searle 
Mark III liquid scintillation spectrometer. 
Electrophoresis: nRNA was resolved by electrophoresis in cylindrical 
polyacrylamide gels (0.4 X 7 cm) containing: 8% (w/v) acrylamide, 
0.32% (w/v) diallyltartardiamide, 6 M urea, 0.1% (w/v) SDS, 0.2% (w/v) 
ammonium persulfate, 0.04% (v/v) N, N, N', N'-tetramethylenediamine, 
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0.4 M Tris-acetic acid (pH 7.2), 0.02 M sodium acetate, and 0.002 
M EDTA. RNA samples containing one unit were mixed with sample 
buffer to give a final concentration of: 0.04 M Tris-acetic acid 
(pH 7.2), 0.02 M sodium acetate, 0.002 M EDTA, 0.02% bromphenol blue 
and 20% (w/v) sucrose (RNase-free). Gels were electrophoresed at 4mA/gel 
at 4° C. Gels were sectioned into 2 mm slices, dissolved in 2% (w/v) 
periodic acid at 37° C for 15 minutes, mixed with 10 ml Aquasol, and 
counted in a Searle Mark II liquid scintillation spectrometer. 
Thin-Layer Chromatography: 4S RNA was isolated by polyacrylamide gel 
electrophoresis. 4S RNA was sliced from the appropriate section of the 
gel and sectioned into 2 mm slices. RNA was extracted from four gel 
slices with 1 ml of RNA extraction buffer (0.1% SDS: 0.014 M NaCl: 
0.025 M sodium acetate, pH 5.1) by continuous vortexing at room 
temperature for one hour. The gel was removed by centrifugation at 
16,000g for 2 minutes in an Eppendorf centrifuge, and the RNA was 
precipitated at -20° C for 2 hours. Enzymatic digestion was carried 
out for 18 hours at 37° C in 20 ul of 0.05 M Tris-HCl (pH 8.0): 5mM 
MgCl^ containing: 6 ug RNase A, 5 ug calf intestine alkaline phos¬ 
phatase (1000 units/mg) and 10 ug snake venom phosphodiesterase. 
Samples were freeze dried and reconstituted with 20 ul of a standard 
mixture containing the eight methylated nucleosides at a concentration 
of 0.4 mg/ml. An aliquot of 5 ul was spotted on 0.25 mm silica gel 
plates containing fluorescent indicator (EM Laboratories, Elmsford, 
New York), and the eight methylated nucleosides were separated by two- 
dimensional thin-layer chromatography with acetonitrile-concentrated 
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NH^OH (4:1, v/v) for the first dimension and acetonitrile-2 N HCOOH 
(10:1, v/v) for the second dimension. Silica gel was recovered from 
the area corresponding to the appropriate standard, mixed with 10 ml 
of Aquasol, and counted in a Searle Mark III liquid scintillation 
spectrometer. 
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RESULTS 
Initial experiments were designed to assess the effects of tubercidin, 
8-azaadenosine, and formycin on total RNA and DNA synthesis in the presence 
and absence of 1 X 10 Si dCF (Fig. VIII). It is apparent that inhibition 
of both RNA and DNA synthesis by 8-azaadenosine and formycin are 
potentiated in the presence of the adenosine deaminase inhibitor, while 
tubercidin inhibited the synthesis of both of these macromolecules to 
the same extent irrespective of pretreatment with 1 uM dCF. Lower 
doses of tubercidin inhibited DNA synthesis more than RNA synthesis but 
as the dose was increased the synthesis of both RNA and DNA became 
inhibited to the same degree with an IC^ °f approximately 7 X 10 
for both macromolecules. In the presence of dCF, 1 X 10 ^ and 1 X 10 
8-azaadenosine inhibited RNA synthesis by 40% but DNA synthesis by only 
-4 -3 
10%-15%. Similarly, 1 X 10 M and 1 X 10 M formycin plus dCF inhibited 
RNA synthesis by 40%-80% and DNA synthesis by 30%-40%. 1 X 10 
dCF, which was used throughout all the experiments, did not affect RNA 
or DNA synthesis. 
To examine the effects of these analogs on RNA synthesis and 
3 
methylation, nRNA was double-labeled with L-[ methyl- H] methionine and 
14 
[ C] uridine, and the alkaline hydrolysates chromatographed on DEAE 
Sephadex (Table 1, Fig. IX). All three drugs preferentially inhibited 
14 
methylation relative to [ C] uridine incorporation only in the 
mononucleotide fraction (-2 charge) representing methylated bases. This 
differential inhibition was not evident in either the dinucleotide fraction 
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(-3 charge) representing 2'-O-methylation, or in the tetranucleotide 
fraction (-5 charge) representing 5’ cap structures. Alkaline 
hydrolysates from cells treated with dCF plus formycin demonstrated an 
3 
additional peak containing 1.7% of the total incorporated [ H] radio¬ 
activity which eluted before the mononucleotide (-2) peak (Fig. IX 
panel D). This material was not characterized further. 1 X 10 
dCF did not affect the synthesis or methylation of nRNA. 
Because of the observation that tubercidin, dCF plus 8-azaadenosine, 
and dCF plus formycin preferentially inhibited base methylation, nRNA 
was next fractionated using electrophoresis in denaturing polyacrylamide 
gels to determine if these effects were largely restricted to 4S nRNA 
which is rich in methylated bases (Table 2, Fig. X). At 4 X 10 
14 
tubercidin, methylation was preferentially inhibited relative to [ C] 
uridine incorporation for both >18S nRNA and 4S nRNA. 1 X 10 \ 
8-azaadenosine plus dCF; however, preferentially inhibited methylation 
-4 
for only >18S nRNA, while 1 X 10 formycin plus dCF preferentially 
inhibited the methylation of only 4S nRNA. By increasing the concentration 
of these drugs 10 fold, the preferential inhibition of methylation 
relative to synthesis was no longer observed, with the exception of the 
effect dCF plus 8-azaadenosine on >18S nRNA. By considering only the 
14 -6 [ C] uridine incorporation data, it is apparent that 4 X 10 M 
tubercidin inhibited the synthesis of >18S nRNA and 4S nRNA to 
approximately the same extent, but when the dose was increased to 4 X 10 
the synthesis of 4S nRNA was more severely inhibited (Table 2). dCF 
-5 14 
plus 1 X 10 M 8-azaadenosine appeared to inhibit [ C] uridine 
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incorporation into 4S nRNA more than >18S nRNA, but at a 10 fold 
higher dose no differential inhibition of the synthesis of these two 
-4 
classes of nRNA could be detected. In the case of dCF plus 1 X 10 M 
formycin; however, 4S nRNA synthesis was inhibited to a greater degree 
than >18S nRNA synthesis, and this differential inhibition of low 
molecular weight nRNA was also observed at the 10 fold higher dose. 
To determine if these drugs inhibited the same, or a different 
spectrum of base methylating enzymes, methylated nucleosides isolated 
from 4S nRNA were resolved by two-dimensional thin-layer chromatography 
(Table 3). It appears that the degree of methylation of m^A was 
_6 
relatively unaffected by any of these drugs. 4 X 10 M tubercidin 
appeared to markedly affect the methylation of most of the other 
5 5 
nucleosides rather broadly, with the possible exception of m C and m U. 
dCF plus 1 X 10 \ 8-azaadenosine seemed to have a more specific effect, 
3 
inhibiting the methylation of m C more severely than the other nucleosides. 
-4 
dCF plus 1 X 10 M formycin; however, appeared not to markedly inhibit 
3 
the methylation of m C, as did tubercidin and dCF plus 8-azaadenosine, 
but did severely inhibit the methylation of m^C, which the other two 
drugs appeared not to do. Other than this apparently specific effect, 
-4 
dCF plus 1 X 10 M formycin markedly inhibited the methylation of most 
1 3 
of the nucleosides with the exception of m A and m C mentioned earlier, 
2 5 
and possibly m G and m U as well. 
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DISCUSSION 
In examining the affects of tubercidin, 8-azaadenosine, and formycin 
on total RNA and DNA synthesis as measured by incorporation of labeled 
uridine and thymidine respectively into TCA precipitable material, it 
was determined that the effects of both formycin and 8-azaadenosine 
were potentiated by dCF, while tubercidin was insensitive to the action 
of this adenosine deaminase inhibitor. These results are consistent 
with the high level of adenosine deaminase in L1210 cells and are in 
agreement with the data obtained by Adamson who demonstrated that 
8-azaadenosine and formycin, but not tubercidin, inhibited the growth 
of P388 mouse leukemia cells to a greater extent in the presence of 
dCF (Lepage, 1969; Adamson, 1977). Also in support of this data are 
the numerous in Vitro studies demonstrating that tubercidin is not a 
substrate for purified adenosine deaminase, while 8-azaadenosine and 
formycin are. As discussed under Cellular Metabolism, 8-azaadenosine 
is extensively metabolized to 8-azaguanine nucleotides by what appears 
to be pathway III in (Fig. II). dCF, however, would block pathway III 
and it can be assumed, in the absence of unknown purine pathways, that 
the effects of 8-azaadenosine on dCF pretreated cells are in fact due 
to 8-azaadenosine, and not some other metabolic product. 
From the gel electrophoresis study it appears that lower dose 
tubercidin inhibited the synthesis of >18S nRNA and 4S nRNA to the same 
extent, while at the higher dose 4S nRNA was more specifically inhibited. 
The "high molecular precursor RNA" reported by Seibert to be isolated 
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only from tubercldin treated, but not from control, L5178y mouse tumor 
cells was not observed In this study (Fig. X panel B) (Seibert, 1975). 
■k 
Specific inhibition of 4S RNA synthesis was also observed with formycin, 
both at high and low doses, while 8-azaadenosine probably did not 
specifically inhibit the synthesis of one species of nRNA vs the other 
since no consistent dose effect relationship could be ascertained. 
The observation that formycin specifically inhibits the synthesis 
of low molecular weight RNA has also been made in HeLa cells and in the 
posterior silk gland of the silk worm Bombyx mori (Abelson, 1973; 
Majima, 1977). The results obtained by Majima and Tsutsumi (1978) 
suggesting that in formycin treated silk glands precursor tRNA did not 
process to the mature 4S form, and that it was degraded by a scavenger 
mechanism, forces one to interpret with caution RNA synthesis data 
14 
based on f C ] uridine incorporation into TCA precipitable material. 
Although no data exists that tubercidin or 8-azaadenosine treated cells 
produce unstable RNA, it is not unreasonable to assume in absence of 
data to the contrary, that these drugs may also cause the synthesis 
of unstable RNA, later to be degraded by some scavenger pathway. 
Weiss, Majima, and Tsutusmi proposed that the mechanism of inter¬ 
ference in RNA processing in tubercidin and formycin treated cells was 
due to incorporation of these analogs into RNA leading to molecules 
*In this section, when results of this study are referred to, 
formycin = formycin + dCF data, and 8-azaadenosine = 8-azaadenosine + dCF 
data. 
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with anomalous properties. In this study tubercidin, formycin, and 
8-azaadenosine all were shown to preferentially inhibit base methylation 
relative to synthesis of nuclear RNA, supporting the hypothesis that 
defective methylation may be the common denominator for the interference 
in RNA processing observed in drug treated cells. It is interesting to 
note in this regard that formycin, which was reported to interfere with 
the processing of pre-tRNA to tRNA (Majima, 1977), preferentially inhibited 
-4 
the methylation of 4S nRNA at a dose of 1 X 10 M (Table 2). 
If degradation of unstable RNA is occurring, and especially if 
it is undermethylated precursors that are being degraded, then the 
3 14 
ratio of [ H methyl] methionine to [ C] uridine incorporation will be 
artificially increased, and one would interpret this as there being 
a less specific effect on the inhibition of methylation vs synthesis. 
For instance, the base methylation data (-2 charge) in (Table 1; 
Fig. IX, panels B,C,D) would demonstrate an even more pronounced specific 
inhibition of methylation compared to synthesis in the absence of these 
conjectural degradative pathways. Since 2'-0-ribose methylation is 
believed to protect RNA from nucleolytic degradation, it is possible 
that in the drug treated cells the lack of a specific inhibition of 
14 
ribose methylation relative to [ C] uridine incorporation in the 
dinucleotide fraction (-3 charge) may be an artifact due to degradation 
of molecules lacking appropriate 2*-0-ribose methylations. 
As mentioned previously, the lower dose of formycin used preferentially 
inhibited the methylation of 4S nRNA relative to > 18S nRNA (Table 2). 
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8-azaadenosine had the opposite effect, specifically inhibiting the 
methylation of > 18S nRNA, while tubercidin appeared to inhibit the 
methylation of both of these species to the same extent. This specificity 
of inhibition was largely abolished at the higher concentrations of 
the drugs used, probably because of the severe inhibition of RNA synthesis 
at the higher dose, except for 8-azaadenosine treated cells which 
maintained a comparable rate of RNA synthesis at the two concentrations 
investigated. 
Examination of the methylated nucleosides contained in 4S nRNA 
suggested that each drug inhibited its own spectrum of RNA methylating 
enzymes (Table 3). While the 4S nRNA species isolated from the 8% 
denaturing polyacrylamide gels was not characterized further, it most 
probably represents precursor tRNA as well as some small nuclear RNA 
species and possibly mature tRNA, since these gels are not capable 
of resolving 4S from 4.5S RNA species. It is apparent that neither 
tubercidin, 8-azaadenosine, nor formycin inhibited m"*~A to any significant 
degree. If the assumption is made that L1210 cells process precursor 
tRNA to tRNA by the same scheme of time and position ordered base 
methylations worked out for KB cells by Munns (1975), then by comparing 
the data in (Table 3) to this scheme certain generalizations with 
respect to inhibition of groups of enzymes may become apparent. Both 
tubercidin and formycin more severely inhibited the methylation of those 
nucleosides clustered around the junctions of the major arms, and m^G 
which is found only in the extra arm, those methylations occurring early 
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in pre-tRNA processing (Fig. VII). These methylated bases are also 
related by the fact they are all guanine nucleosides. In addition to 
this effect, tubercidin also inhibited to a greater extent those 
bases clustered in the anticodon loop and dihydrouridine arm, the late 
stage methylations. Formycin showed relative sparing of this region, 
but demonstrated severe inhibition of m^C, which neither tubercidin 
nor 8-azaadenosine appeared to do. It is interesting to note that 
8-azaadenosine showed the most specific effect on the inhibition of 
3 
base methylation, where m C was inhibited the most of the 8 methylated 
nucleosides examined. 
With respect to structure activity correlation, the drugs in 
(Table 3) are arranged in order of increasing glycosyl bond length and 
increasing glycosyl torsion angle from top to bottom. Increasing the 
glycosyl bond length and torsion angle is theoretically associated with 
increasing freedom of rotation around the glycosyl bond, allowing the 
compound to assume either the syn or anti conformation. When the data 
are examined in this way no pattern of inhibition of methylated 
nucleosides becomes apparent. Formycin, unique amongst the compounds 
studied with its C-C glycosyl bond, seemed to inhibit the methylation 
5 3 
of m C more and m C less than the other analogs. 8-azaadenosine, the 
3 
only triazolo nucleoside investigated, seemed to affect m C more 
specifically than the other drugs. 
When the synthesis and methylation of > 18S nRNA and 4S nRNA are 
examined with respect to the structural variables of glycosyl bond 
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length and torsion angle, again no pattern of inhibition of synthesis 
or methylation becomes apparent. 8-azaadenosine did not show specificity 
in inhibition of nRNA synthesis as did formycin and higher dose 
tubercidin, but did show specificity in the ability to inhibit the 
methylation of >18S nRNA. 
Several studies have shown that tubercidin, 8-azaadenosine, and 
formycin are all extensively metabolized in cells and the question 
arises as to whether the inhibition of methylation of nRNA observed in 
this study is due to the direct effects of these drugs, or to some 
metabolic product. While this question was not addressed experimentally 
in this study, examination of (Fig. XI), which summarizes the eucaryotic 
cellular metabolism of S-adenosylmethionine (SAM) and S-adenosylhomocysteine 
(SAH), brings several speculations to mind. The first possibility, 
alluded to earlier, is that these drugs directly inhibit the SAM dependent 
RNA methyltransferases. Alternatively, they or their nucleotide derivatives 
could inhibit methionine adenosyltransferase, and by lowering the 
intracellular concentration of SAM, inhibit more severely those methyl- 
transferases with a higher Km for SAM. If the triphosphate derivatives 
of these drugs are suitable substrates for methionine adenosyltransferase, 
then the formation of an analog containing counterpart of SAM may lead 
to a molecule capable of inhibiting the methyltransferase enzyme. 
Lastly, by progressing further along the pathway shown in (Fig. XI), the 
homocysteinyl derivative of the analog would be formed, and it is possible 
that it is the homocysteinyl derivative of tubercidin, 8-azaadenosine, 
and formycin that is responsible for inhibiting the RNA methyltransferases. 
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Using a crude preparation of tRNA methyltransferases isolated from 
rat liver, SAH and S-tubercidinylhomocysteine (STH) were shown to have 
almost identicle Ki values, 25 uM and 20 uM respectively (Coward, 1974). 
When more purified methyltransferases from the same source were examined, 
8-azaadenosylhomocysteine was shown to be a better inhibitor of 
adenine-1 methyltransferase than STH or SAH, but STH and SAH were the 
2 
superior inhibitors of N -guanine-I and guanine-1 methyltransferase 
respectively (Leboy, 1978). In another methyltransferase reaction, 
STH inhibited Newcastle Disease Virion mRNA (guanine-7-)-Methyltransferase 
with a Ki 36% of SAH, while 8-azaadenosylhomocysteine inhibited this 
methyltransferase with a Ki 8.5X larger than SAH (Pugh, 1977). 
Several authors have demonstrated that STH is capable of inhibiting 
in Vivo RNA methylation. STH was shown to inhibit base methylation, as 
well as 2’-0-ribose methylation, as determined by the appearance of 
cap 0 and decreased amounts of cap 2 structures in cytoplasmic poly A 
containing RNA isolated from treated Novikoff hepatoma cells (Kaehler, 
1977). Phytohemagglutinin-stimulated rat lymphocytes exposed to STH 
demonstrated a 49% inhibition of methylation of tRNA, and when the 
methylated nucleosides of tRNA isolated from STH treated Novikoff 
2 7 
hepatoma cells were examined, m^G and m G showed 90% and 83% inhibition 
of methylation respectively, while m^A and m^U were uninhibited (Chang, 
1975; Coward, 1979). This is an interesting result when compared to 
the data obtained in this study where tubercidin inhibited the methylation 
2 7 15 
of m^G and m G to a greater extent than m A and m U. 
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The question of whether tubercidin of S-tubercidinylhomocysteine is 
responsible for inhibiting methylation is most directly addressed by 
the research of Kaehler who studied the methylation of poly A containing 
RNA isolated from Novikoff hepatoma cells treated with either homocysteine, 
adenosylhomocysteine, tubercidin, or tubercidinylhomocysteine (Kaehler, 
3 
1979). By examining the ratio of the incorporation of [ H-methyl] 
14 
methionine to [ C] uridine, Kaehler showed that STH had specifically 
14 
inhibited methylation relative to [ C] uridine incorporation, while 
tubercidin did not. In this study, 4 X 10 tubercidin was shown to 
abolish the preferential inhibition of methylation of > 18S nRNA observed 
at 4 X 10 Si, and it is possible that the lack of specific inhibition 
of methylation observed by Kaehler using tubercidin at a dose of 2.5 X 
-4 
10 M was due to too high a dose of tubercidin. In reference to 2’-0-ribose 
methylation, Kaehler further demonstrated that cap 0 structures were 
isolated only from STH, but not tubercidin treated cells; however, 
tubercidin treated cells demonstrated 13X and 20X more cap 2 structures 
than control or STH treated cells respectively. In this study tubercidin 
appeared not to specifically inhibit 2’-0-ribose methylation (Table 1, 
-3 charge; Fig. IX, panel B), but as discussed earlier possible degradation 
of RNA lacking appropriate 2'-0-ribose methylation may have obscured any 
specificity in the inhibition of 2'-0-ribose methylation by tubercidin. 
The DEAE sephadex-urea chromatography technique used in this study was of 
insufficient resolving power to separate the different species of 5' 
caps and so no conclusions can be made in reference to them. 
In summary, other studies have shown that tubercidin and formycin 
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interfere with RNA processing and it has been suggested that incorporation 
of these drugs into RNA is responsible for this effect. In this 
investigation tubercidin and formycin, as well as 8-azaadenosine, were 
shown to inhibit the methylation of nuclear RNA in L1210 mouse leukemia 
cells by a mechanism that remains unknown at present. This inhibition 
of methylation of nRNA suggests an alternative hypothesis whereby the 
production of defectively methylated RNA is responsible for the reported 
interference in RNA maturation by these drugs. It would be interesting 
to investigate other agents that interfere with RNA processing to see 
if they too have any effect on the methylation of RNA. Alternatively 
tubercidin, 8-azaadenosine, and formycin, because of their ability to 
inhibit RNA methylation, may prove useful in probing the role of 
methylation in the fascinating process of RNA maturation. 
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-PART FOUR- 
FIGURES AND TABLES 
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STRUCTURE OF 
TUBERCIDIN, FORMYCIN, AND 8-AZAADENOSINE 
HO OH HO OH 
Syn Anti 
TUBERCIDIN 
FORMYCIN 8-AZAADENOSINE 
Figure I 
Dashed bonds in tubercidin illustrate angles used in the calculation 
of the glycosyl torsion angle. 
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Eucaryotic Purine Metabolism 
Xanthine 
,,oxidase 
URIC ACID 
Figure II 
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METABOLISM OF FORMYCIN A 
Ribose 
Adenosine 
deaminase 
Ribose 
Hepatic 
Aldehyde 
(r oxidase 
Ribose 
Figure III 
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Structure of the 5'Terminal Cap 
NH 
0= P- o-ch2 x 
*■ w 
O’ OH 
Figure IV 
7Me 2' OMe 
Illustrated is the structure of G(5')ppp(5')A^ ^ pApX, a Cap 1 structure. 
6 
Filled squares are methyl groups. Arrow indicates position of additional 
7Me 
methyl group forming cap 2. Cap 0 would have only terminal G(5')ppp(5’)X, 
(Lewin, 1980). 
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:a.r. 
Synthesis of the 5'Terminal Cap 
Gppp + (ppApNp-or pppApNp-) 
Guanyly I 
transferase 
GpppApNp - 
SAM- 
SAH 
7 Me 
7- Methyltransferase 
GpppApNp 
SAM 
SAH 
7Me GpppA 
SAM 
SAH 
7Me 
2'-0- Methyltransferase 
[ 2'0Me 
' r 
GpppA 
pNp- 
2'-0- Methyladenosine 
g 
N methyltransferase 
2'OMe 
PNP- N Me 
Figure V 
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Illustration of Eucaryotic RNA Processing 
Figure VI 
Ribosomal RNA processing sequence as determined in HeLa cells 
(Lewin, 1980). 
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Structure of Transfer RNA 
DHU 
Arm 
Amino 
Acid 
Arm 
A 
C 
C 
T¥C 
Arm 
A early 
o intermediate 
□ late 
Figure VII 
y = pseudouridine, DHU = dihydrouridine. Early, intermediate, and 
late refer to stages of base methylation in tRNA maturation as determined 
by Munns (1975). 
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DOSE-RESPONSE OF RNA AND DNA SYNTHESIS BY TUBERCIDIN, 8-AZAADENOSINE 
AND FORMYCIN 
O 
cc 
O 
u 
10 -6 10 -5 10' 
CONCENTRATION (M) 
10 -3 
Figure VIII 
L1210 cells (1 X 10^ cells/flask) were preincubated with or without 
(0,0) 1 X 10~6M dCF, and incubated for 30 minutes with tubercidin (A), 
8-azaadenosine (B) or formycin (C). Cells were then double-labeled for 1 
hour with [^C] uridine (0,9) and [^H] thymidine and TCA-precipitable 
radioactivity was determined as described under Materials and Methods. Each 
value is the mean of two to three determinations. 
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DEAE SEPHADEX-UREA CHROMATOGRAPHY OF ALKALINE HYDROLYSATES OF nRNA 
o 
< 
cr 
Figure IX 
L1210 cells (5 X 107 cells/flask) were preincubated for 15 minutes 
with (C and D) or without (A and B) 1 X 10_6M dCF and incubated for 
30 minutes with 4 X 10“6M tubercidin (B) , IX 10-;)M 8-azaadenosine (C) , 
or 1 X 10“^M formycin (D). Cells were then double-labeled for 1 hour 
with 200 uCi L-[methyl-3H] methionine and 5 uCi I14C] uridine. DEAE 
sephadex-urea chromatography as described under Materials and Methods. 
The -2, -3, -4, and -5 markers represent the net charge of mono, di, 
tri, and tetranucleotides, respectively, eluted with the NaCl gradient. 
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Table 1. DEAE Sephadex-urea chromatography of alkaline hydrolysates of nRNA 
from L1210 cells treated with tubercidin, 8-azaadenosine and formycin* 
RNA fraction (103 d.p.m.) 
-2 -3 -5 
Treatment ■Hi 14c Hi 14c 3h 14c 
Control 268 + 28 110 + 6 186 + 19 4.15 + 0.91 20.6 + 1.7 0.55 + 0.16 
X of control 
Tubercidin 
4x10"6M 59 99 77 53 47 0 
4x10'5M 9 16 14 2 8 0 
dCF+8-Azzadenosine 
-5 
1x10 M 45 62 57 42 29 26 
1x10"4M 50 61 61 43 35 0 
dCF+Formycin 
1x10“4M 28 73 59 21 26 0 
1x10“3M 14 38 32 10 14 0 
♦Values for pooled controls (with and without dCF) represent the means + S.E. of four determinations. 
Values for incubations with the lower concentration of each drug represent the mean ot two determinations, and 
at the higher concentration of each drug a single determination. L1210 cells were incubated with tubercidin, 
dCF + 8-azaadenosine, or dCF + formycin followed by labeling with L-[roethyl-^H] methionine and [ C] uridine 
as described under Materials and Methods. The fractions -2, -3, and -5 denote the net charge of mono, di, 
and tetranucleotides of alkaline hydrolysates of nRNA eluted by DEAE Sephadex chromatography depicted in 
(Fig. IX). 
71 

POLYACRYLAMIDE GEL ELECTROPHORESIS OF nRNA 
Figure X 
L1210 cells (5 X 10^ cells/flask) were treated as described in (Fig. IX) 
and electrophoresed in denaturing 8% polyacrylamide-urea gels as described 
under Materials and Methods. 
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Table 2. Effects of tubercidln, 8-azaadenoslne and formycin on the 
methylation and synthesis of nRNA from L1210 cells* 
RNA fraction (2 of control) 
Total >18S 4SRNA 
Treatment 
14, 14 
C 
14 
C 
Tubercidin 
4x10~6M 
4x10_5M 
dCF+8-Azaadenosine 
1x10_5M 
1x10~AM 
dCF+Fonnycin 
1x10_AM 
1x10_3M 
57+2 85+2 
16+3 8+2 
47+2 62+2 
42+3 63+4 
33 + 2 55 + 2 
27 + 1 35 + 1 
50 + 5 75 + 8 
15+3 15+3 
45+4 70+9 
32+3 58+10 
52+7 57+4 
22+6 32+8 
43+3 61+8 
14 + 4 2 + 1 
38 + 6 40 + 10 
30+8 40+12 
25+1 41+4 
14+3 12+2 
♦Values represent the means + S.E. of three to six determinations. L1210 cells were incubated with 
tubercidin, dCF + 8-azaadenosine, or dCF + formycin followed by labeling with L-[methyl- H] methionine and 
[14C] uridine as described under Materials and Methods. Nuclear RNA was isolated and electrophoresed in 
82 polyacrylamide-urea gels as depicted in (Fig. X). Radioactivity in > 18S and 4S nRNA was calculated 
from the radioactivity present at the top of the gel and the 4S region, respectively. 
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Table 3. Effects of tubercidln, 8-azaadenoslne and formycin on the 
composition of methylated nucleosides in 4S nRNA from L1210 cells* 
Methylated nucleoside (d.p.m.) 
Treatment 
m^G m^C m3C m2G m2G m^G m5U 1. m A 
Control 3230 2220 630 4590 4290 2520 3430 300 
Tubercidln 
4x10-6M 20 54 
/ of control 
27 32 36 28 41 88 
dCF+8-Azaadenosine 
1x10_5M 47 42 27 55 50 42 53 93 
dCF+Formycin 
1x10_4M 25 9 40 30 17 19 31 83 
*Each value is the mean of two determinations. Thin-layer chromatography and determination of 
radioactivity as described under Materials and Methods. 
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I amp! 
Eucaryotic Metabolism of S-Adenosylmethionine 
and S-Adenosylhomocysteine 
Methyl —v. 
acceptor 
Methylated^' 
acceptor 
|S-ADENOSYLHOMOCYSTEINE | 
0 Adenosylhomocysteinase 
I ADENOSINE 
Adenosine kinase I 
-or--I ADA 
Purine 
Nucleoside 
phosphorylase 
APfijT 
I NOSINE 
l 
I 
I 
Homocysteine1 
methyltetrohydrofolote 
methyltronsferose 
/ M«BI2 
/ N5-Me-FH4 
I METHIONINEl 
Cystothionine 
0 synthetase 
CYSTATHIONINE 
/ \ 
ICYSTEINEl a-KETOBUTYRIC 
ACID 
Figure XI 
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